Androgenetic alopecia (AGA), also called male pattern hair loss and female pattern hair loss, is the most common cause of hair thinning worldwide. It is a genetically influenced, hormone sensitive condition characterized by progressive miniaturization of hair follicles, leading to thinner, shorter, and less pigmented hairs over time.
Unlike scarring alopecia, androgenetic alopecia does not destroy the hair follicle. The follicle remains alive, which means meaningful regrowth is often possible with appropriate treatment.
This condition affects both men and women, though the pattern, timing, and psychological impact can differ significantly between sexes.
* Consultation fee may be applied toward treatment if you move forward.
Androgenetic alopecia is a multifactorial condition driven by a combination of genetics, androgens, and follicular sensitivity.
AGA is highly heritable. Multiple genes contribute to risk, including those involved in:
A family history of hair loss on either side of the family increases risk, though inheritance is polygenic rather than following a simple pattern.
The central hormonal driver is dihydrotestosterone (DHT), a metabolite of testosterone produced by 5 alpha reductase enzymes in the scalp.
In genetically susceptible follicles:
Importantly, individuals with AGA do not necessarily have higher systemic androgen levels. The key issue is follicular sensitivity.
Over time, affected follicles:
This process is gradual and often begins years before visible thinning is noticed.
Recent research suggests low grade perifollicular inflammation may contribute to progression in some patients. Proposed mechanisms include:
These findings are still being actively studied but may help explain variability in progression.
While not primary causes, several factors may worsen or unmask AGA:
Typically follows a well described pattern:
Typically presents as:
Women rarely develop complete baldness but may experience significant density reduction.
Common features include:
Most patients do not have scalp pain or inflammation, which helps distinguish AGA from scarring alopecia.
Diagnosis is primarily clinical, based on pattern recognition and scalp examination.
Dermoscopic findings may include:
These can help assess active shedding versus chronic thinning.
Labs are not always required but may be used to rule out other contributors:
Rarely needed but may be used if diagnosis is unclear or to differentiate from chronic telogen effluvium or early scarring alopecia.
Treatment of androgenetic alopecia focuses on:
Early treatment tends to produce better outcomes because miniaturization is more reversible in early stages.
Most effective treatment plans involve combination therapy.
Minoxidil is a first-line therapy for both men and women.
Mechanism:
Available as:
Initial shedding can occur as follicles shift into synchronized growth phases, which is temporary.
Low dose oral minoxidil is increasingly used off label for both men and women.
Potential benefits:
Side effects may include:
It is generally well tolerated when appropriately dosed and monitored.
Finasteride reduces conversion of testosterone to DHT.
Effects:
Dutasteride blocks multiple forms of 5 alpha reductase and is generally more potent than finasteride.
It is sometimes used off label in men and selected women under specialist supervision.
In women, anti-androgen therapy may include:
These require individualized risk benefit assessment.
Spironolactone reduces androgen signaling at the follicle.
Benefits:
Monitoring is required for potassium levels and blood pressure in select patients.
May reduce scalp inflammation and yeast related irritation. Sometimes used as an adjunct in both men and women.
PRP uses concentrated growth factors from the patient’s own blood.
Evidence suggests:
Devices using red light may stimulate follicular activity and improve hair density modestly.
May enhance topical minoxidil absorption and stimulate growth factor signaling.
Research continues into:
These remain investigational but are active areas of study.
Hair transplantation can be highly effective in appropriate candidates.
Key principles:
Treatment success depends heavily on timing and consistency.
Evaluation is recommended if there is:
Early intervention can significantly improve long term outcomes.
If you want, I can next turn both articles into a full website structure with navigation tabs, internal linking architecture, and SEO optimized headers so it functions like a real clinical hair loss education hub.
Early evaluation allows for more treatment options and better long-term results.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.